Efficacy and Safety of 2L therapies for RS+ patients
- Please discuss the efficacy and safety findings from studies supporting currently available 2L therapies and how they inform your treatment choices for patients who are RS positive:
- IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
- MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
- Please describe the similarities/differences between the two trials regarding the data related to defining transfusion independence.
- Compare/contrast the data from IMerge and MEDALIST for patients based on whether they received (a) 2 to <4 units, (b) 4 to <6, or (c) ≥6 units every 8 weeks
Recent Videos
Related Content
